Innate Pharma (IPHA) Beginning Cash Balance (2020 - 2025)
Innate Pharma's (IPHA) quarterly Beginning Cash Balance came in at $77.3 million in Q4 2025, up 2.44% YoY from $75.4 million in Q4 2024, and up 2.44% on a QoQ basis from $75.4 million in Q4 2024.
Innate Pharma (IPHA) Beginning Cash Balance (2020 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 6 years of Beginning Cash Balance data on file, last reported at $77.3 million in Q4 2025.
- Quarterly Beginning Cash Balance rose 2.44% year-over-year to $77.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $349.2 million (down 18.49% YoY) and the FY2025 annual result came in at $77.3 million, up 2.44% from the prior year.
- Beginning Cash Balance improved to $77.3 million in Q4 2025, from $75.4 million in the prior quarter.
- In the past five years, Beginning Cash Balance ranged from a high of $156.5 million in Q4 2021 to a low of $75.4 million in Q4 2024.
- A 5-year average of $101.1 million and a median of $90.6 million in 2023 frame the typical range for Beginning Cash Balance.
- Annual changes were most pronounced in 2021 — Beginning Cash Balance plunged 35.31% — and 2025, when it rose 2.44%.
- Tracing IPHA's Beginning Cash Balance over 5 years: stood at $156.5 million in 2021, then plunged by 32.35% to $105.9 million in 2022, then dropped by 14.39% to $90.6 million in 2023, then fell by 16.74% to $75.4 million in 2024, then grew by 2.44% to $77.3 million in 2025.
- The last three Beginning Cash Balance figures came in at $77.3 million (Q4 2025), $75.4 million (Q4 2024), and $90.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77.29 Mn |
| Dec 31, 2025 | 77.29 Mn |
| Dec 31, 2024 | 75.45 Mn |
| Dec 31, 2024 | 75.45 Mn |
| Dec 31, 2023 | 90.62 Mn |
| Dec 31, 2023 | 90.62 Mn |
| Dec 31, 2022 | 105.86 Mn |
| Dec 31, 2022 | 105.86 Mn |
| Dec 31, 2021 | 156.49 Mn |
| Dec 31, 2021 | 156.49 Mn |
| Dec 31, 2020 | 241.90 Mn |
| Dec 31, 2020 | 241.90 Mn |